Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

Osteoporosis International

Volumn 13, Issue 12, 2002, Pages 925-931

  Reginster, J Y ^a,c   Deroisy, R ^a   Dougados, M ^b   Jupsin, I ^a   Colette, J ^a   Roux, C ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Universite Rene Descartes ^*  (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bone mineral density; Menopause; Osteoporosis; Prevention; Strontium ranelate

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; PLACEBO; STRONTIUM; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

ABSORPTIOMETRY; ADULT; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERANCE; FEMALE; FEMUR NECK; GENDER; HIP; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; X RAY ANALYSIS;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; TREATMENT OUTCOME;

EID: 0036922499     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200129     Document Type: Article

References (16)

1. Parfitt AM, Mundy GR, Roodman GD, et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996;11:150-9.
2. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
3. Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J-Y, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
4. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607-15.
5. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;11:1302-11.
6. Grynpas MD, Hamilton E, Cheung R, et al. Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone 1996;18:253-9.
7. Meunier PJ, Slosman D, Delmas PD, et al. Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis: A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
8. Amman P, Rizzoli R, Deloffre P, Tsouderos Y, Meyer JM, Bonjour JP. Long-term administration of a high dose of the strontium salt S12911 has no toxic effect on bone biomechanics in female rats and may improve bone strength of the midshaft humerus. J Bone Miner Res 1995;10(S1):358.
9. Pors-Nielsen S, Slosman D, Sorensen OH, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 1999;2:371-9.
10. Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Amman P, et al. Incorporation and distribution of strontium in bone. Bone 2001;28:446-53.
11. Reginster J-Y, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;II:1469-71.
12. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-92.
13. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935-42.
14. Meunier PJ, Confavreux E, Tupinon I, et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997;82:2784-91.
15. Adami S, Bruni V, Bianchini D, et al. Prevention of early postmenopausal bone loss with cyclical etidronate. J Endocrinol Invest 2000;23:310-6.
16. Boivin G, Schenker E, Tupinon-Mathieu I, et al. Uptake and distribution of strontium in human bone, evolution of the degree of mineralisation after strontium ranelate administration. J Bone Miner Res 1999;14(Suppl 1):284.